Multiple Sclerosis Resource Centre
  • Home
  • About MS
  • MSRC Services
  • Get Involved
  • MS Research News
  • MSRC Groups
  • Useful Resources
  • Welcome To Josephs Court, MS Centre Of Excellence
  • Advertising
  • E-Newsletter
  • Contact Us
  • Cookie Policy
  • Investor in People
    You are here : Home » MS Research News » Drugs » NeuroVax

    NeuroVax

    A A A
    [Print this page]

    Share |


    MS drug NeuroVax partnership discussions terminated

    NeurovaxImmune Response BioPharma, Inc. terminates blockbuster MS drug NeuroVax partnership discusions with GlaxoSmithKline.

    "Immune Response BioPharma, Inc. has the first MS Vaccine a first in class and best in class multiple sclerosis drug which restores deficient FOXP3+ T-Regs. GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money on HGSI and a Lupus drug with poor sales, we don't need them or to give away our blockbuster drug for MS to them which we believe will become treatment of choice"

    "IRBP values NeuroVax north of a billion dollar of annual sales once approved. We will find a solid partner or raise capital on our own, we don't need GSK which has zero experience in multiple sclerosis or auto-immune diseases. GSK is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor. We have decided to terminate any collaboration or development with GSK. GSK is a loser in the MS market and will continue to be a loser" IRBP CEO Mr. Buswell

    Source: Biospace © 2012 BioSpace, Inc (31/05/12)

    Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax(TM) Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
    New Data from Open-Label Study Presented at Federation of Clinical Immunology Societies (FOCIS) Annual Meeting.

    Orchestra Therapeutics, Inc. announced today positive new data from its completed Phase II open-label study of NeuroVax(TM), an investigational T Cell Receptor (TCR) peptide vaccine for the treatment of relapsing-remitting multiple sclerosis (MS). The new data, presented last week at the Federation of Clinical Immunology Societies (FOCIS) annual meeting, showed that monthly vaccinations over one year with NeuroVax(TM) markedly expanded the capacity of regulatory T cells (Tregs) to recognise TCRs expressed by potentially pathogenic T cells. New data were also presented that showed NeuroVax(TM) produced a significant increase in TCR-specific T cells in patients with MS, including increases in interleukin-10-secreting T cells (IL-10) and Foxp3+ Tregs.

    "These new findings provide evidence to support the network hypothesis, in which internal cell-cell recognition of antigen receptors can be greatly expanded in regulatory T cells by activating the system with NeuroVax(TM). These vaccine induced responses may help control the autoimmune processes that are thought to be the main cause of the inflammatory phase of MS" said Arthur A. Vandenbark, M.D., Ph.D., Senior Research Career Scientist at the VA Medical Center, and Professor of Neurology and Molecular Microbiology and Immunology at Oregon Health & Science University in Portland, OR., and lead author on the study. "Increases in both IL-10-secreting T cells and the Foxp3+ Tregs suggest that NeuroVax(TM) can stimulate native thymus-derived Foxp3+ Tregs as well as induce peripheral Foxp3+ Tregs from CD4+CD25- T cells through an IL-10 controlled mechanism."

    "These new data suggest that induction of an expanding population of TCR-reactive, Foxp3+ Tregs by NeuroVax(TM) may be able to exert broad and potent immunomodulatory effects on pathogenic T cells," said Dr. Joseph O'Neill, President and CEO of Orchestra Therapeutics, Inc. "The indication that this vaccine candidate increases both native and induced types of Foxp3+ Tregs against a broad population of pathogenic T cell families is also important as it provides further insight into the targeted mechanism of NeuroVax(TM). Orchestra Therapeutics is investigating how this TCR peptide vaccine technology, pioneered with NeuroVax(TM), could be leveraged to develop similar therapeutic vaccines for other autoimmune diseases such as rheumatoid arthritis (RA) and psoriasis."

    In MS, a specific subset of a patient's own white blood cells, pathogenic T cells, attack myelin, a fatty tissue in the central nervous system, which surrounds and protects nerve fibres. This pathologic process creates multiple areas of inflammation that ultimately lead to scarring (sclerosis) and that interfere with normal transmission of nerve impulses. This nerve damage, in turn, leads to a variety of chronic and often debilitating neurological symptoms, ranging from serious movement and balance problems to vision impairment.

    NeuroVax(TM), which is currently being tested in a double-blind, placebo-controlled 200-patient Phase II study, may represent a significant advance in the treatment of MS, which affects more than 2.5 million people worldwide, including more than 400,000 in the United States. NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax(TM) appears to work in part by enhancing levels of Foxp3+ Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCR peptides combined in NeuroVax(TM) correspond to one or more TCR gene families which are over expressed in 90% of MS patients. Previous clinical trials conducted by the Company and other independent researchers have associated diminished levels of Foxp3+ Treg responses with the pathogenesis and progression of MS. This same mechanism appears to be important in the pathogenesis of other autoimmune diseases such as RA and psoriasis.

    About the Study

    These new mechanistic clinical data are from a recently completed open- label study examining immunological and clinical parameters in 27 NeuroVax(TM) treatment-naïve and nine previously NeuroVax(TM) vaccinated subjects with various forms of MS. Study participants received monthly injections of NeuroVax(TM) over a one year period.

    Source: Orchestra Therapeutics, Inc. (11/06/07)

    The Immune Response Corporation Injects First Patient in Trial of NeuroVax(TM) for Treatment of Multiple Sclerosis
    The Immune Response Corporation today announced the injection of the first patient in a large multi-center Phase II study of NeuroVax(TM), an investigational T-Cell Receptor peptide vaccine for the treatment of relapsing-remitting multiple sclerosis (MS). NeuroVax(TM) may represent a significant advance in the treatment of MS, which affects more than 2.5 million people worldwide, including more than 400,000 in the United States.

    "We are pleased to initiate this important trial," said Dr. Joseph O'Neill, President and CEO of The Immune Response Corporation. "This study will allow us to examine the potential of NeuroVax(TM) to help patients with multiple sclerosis, to better understand our platform technology in autoimmune diseases, and position our MS program for a strong commercial partnership."

    In MS, a specific subset of a patient's own white blood cells, pathogenic T-cells, attack myelin, a fatty tissue in the central nervous system, which surrounds and protects nerve fibres. This pathologic process creates multiple areas of inflammation that ultimately lead to scarring (sclerosis) and that interfere with normal transmission of nerve impulses. This nerve damage, in turn, leads to a variety of chronic and often debilitating neurological symptoms, ranging from serious movement and balance problems to vision impairment.

    NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide vaccine technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax(TM) appears to work by enhancing levels of FOXP3+ regulatory T-cells (Treg cells) which may help regulate expression of pathogenic T-cells in MS patients.

    Previous clinical trials conducted by the Company and other independent researchers have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has proprietary technology and prior clinical experience for evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.

    "By restoring FOXP3+ Regulatory T-cell functions to levels seen in healthy individuals, NeuroVax(TM) may offer a new and highly targeted mechanism to control pathogenic T-cell activity and limit or prevent nerve tissue damage in MS patients," said Dr. O'Neill. "Additionally, NeuroVax(TM)'s once-a-month dosing, attractive side effect profile and ease of manufacture could benefit the millions of MS patients in need of effective and more tolerable treatment options."

    The goal of The Immune Response Corporation's research program is to develop safe, effective and affordable therapies for patients suffering from devastating diseases. The Company's investigational vaccines for MS and other autoimmune diseases, as well as for treatment of HIV, are highly targeted, potentially less toxic medicines that seek to harness the body's own defenses to control and possibly prevent disease. This approach may prove valuable in the discovery of novel immune-based therapies for a host of autoimmune and infectious diseases.

    About the Study

    This trial is a multi-center, randomised, double-blind, placebo-controlled 48-week study to assess the safety and efficacy of NeuroVax(TM). Two hundred subjects with relapsing-remitting MS, with an Expanded Disability Status Scale (EDSS) score of less than or equal to 5.5 and meeting all inclusion/exclusion criteria, will be enrolled in the study in several Central and Eastern European countries. The first trial patient was injected at a study site in Bulgaria and regulatory approval to begin enrolling has been obtained in Slovakia. Enrollment will continue in other countries as pending regulatory approvals to initiate the trial are approved.

    The primary clinical endpoint of the study is to compare the cumulative number of new gadolinium enhancing lesions, a key marker of MS disease activity, using MRI scans at 24, 32, 40, and 48 weeks. Secondary objectives include additional MRI measurements, analysis of clinical relapses, measures of neurologic disability, immunologic evaluations, and safety.

    Study participants will be randomised equally to receive NeuroVax(TM) (100 micrograms/mL of each of three selected TCR Peptides), emulsified in Incomplete Freund's Adjuvant (IFA) or placebo (IFA) intramuscularly in the deltoid muscle every four weeks. Evaluation will occur every eight weeks by brain MRI scan and patients will also undergo evaluation by neurology examinations at 12, 24, 36, and 48 weeks. Safety will be monitored by routine physical exams that will be performed at 24 and 48 weeks, and lab tests of hematology, chemistry panel and urinalysis will be performed at weeks 4, 12, 24, 36, and 48.

    REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.

    Source: FinanzNachrichten © 2000-2007 FinanzNachrichten.de (08/03/07)

    Immune Response Corp launches trial of NeuroVax MS vaccine
    U.S. firm Immune Response Corp. said Tuesday it has secured a contractor for its phase II trial of NeuroVax, a vaccine for multiple sclerosis.

    The company said it has contracted with Accelsiors CRO & Consultancy Services to oversee the study.

    IRC said it would start enrolling patients in the study by the end of the year, eventually recruiting 200 subjects with relapsing-remitting MS.

    The study will be powered to compare the cumulative number of new gadolinium enhancing brain lesions -- a key marker of the disease -- via magnetic resonance imaging scans at 24, 32, 40, and 48 weeks.

    "We are extremely excited at the potential of NeuroVax(TM) to help patients with Multiple Sclerosis," said Krzysztof Selmaj, the study's lead investigator. "This treatment may have the ability to alter how the immune system fights MS and we eagerly anticipate study results that could offer benefit to the millions of MS patients in need of more effective and tolerable treatment options."

    NeuroVax is a T-cell receptor (TCR) peptide vaccine.

    Source: United Press International© Copyright 2006 United Press International, Inc. All Rights Reserved  (11/10/06)

    The Immune Response Corporation's NeuroVax(TM) Restores FOXP3+ T-Cell Levels Believed to Help in MS
    The Immune Response Corporation announced that its T-cell receptor peptide vaccine candidate, NeuroVax(TM), induces increased FOXP3 expression resulting in re-establishment of normal levels of the FOXP3+ regulatory T-cells believed to be important in controlling the development of multiple sclerosis (MS). Results of the recently completed open-label trial in MS patients were presented yesterday by Dr. Dennis Bourdette, Oregon Health and Sciences University (OHSU) Department of Neurology Chair, during an oral presentation at the 58th Annual Meeting of the American Academy of Neurology in San Diego, CA.

    "NeuroVax(TM) is a promising candidate for development as a novel vaccine for treating patients with MS," said Dr. Bourdette, who is also a member of the Company's Scientific Advisory Board guiding the development of NeuroVax(TM). "The TCR peptide vaccine works by down-regulating the pathogenic T-cells causing the MS. Our clinical findings indicate that NeuroVax(TM) induces strong, disease-specific immune responses in essentially all the MS patients treated. The findings indicate that an important part of the strong disease-specific immune response induced by NeuroVax(TM) is the stimulation of FOXP3+ regulatory T-cells. This exciting approach could play an important role in the treatment of MS."

    About the Study

    This one-year open-label trial enrolled 25 patients who received monthly injections of NeuroVax(TM). Seventeen of these were newly-enrolled patients, and showed statistically lower baseline levels of FOXP3+ mRNA measured by RT-PCR (p=0.03) and FOXP3 protein expression by Western blot (p=.02) when compared with healthy controls. Following immunization of these MS patients with NeuroVax(TM), 14/17 patients at 52 weeks demonstrated increased FOXP3+ mRNA expression over baseline (p=0.01) and FOXP3 protein expression as a group was also statistically increased over baseline (p=0.02). In a number of patients, FOXP3 message and protein expression became higher than those in healthy controls. These data indicate that a key portion of the strong immune responses induced in patients given NeuroVax(TM) include increases in expression of FOXP3, a marker which is associated with the activity of CD4+CD25+ regulatory T-cells. NeuroVax(TM) thus may be boosting an important immune regulatory network which may be clinically beneficial for MS patients.

    "These exciting findings on the regulatory mechanism of how NeuroVax(TM) can be influencing the pathogenic T-cells causing MS, coupled with our earlier MRI data that suggest NeuroVax(TM) may decrease the number of total new Gadolinium enhancing lesions, are the basis for the design of a Phase II study that will be initiated later this year in Eastern Europe and the United States that will test the clinical benefit of NeuroVax(TM) by assessing its effect on MRI and relapse rates," commented Dr. Joseph O'Neill, President and Chief Executive Officer of The Immune Response Corporation.

    Source: The Immune Response Corporation (10/04/06)

    The Immune Response Corporation Forms New Scientific Advisory Board for Multiple Sclerosis
    Prestigious Board to Guide Research and Development of NeuroVax(TM)

    March 29, 2006--The Immune Response Corporation announced today that it has formed a Scientific Advisory Board to provide scientific and clinical direction in its development of NeuroVax(TM), its therapeutic product candidate for the treatment of multiple sclerosis (MS).

    "We are honored to have six of the leading minds in MS research working with us to guide the development of NeuroVax(TM)," said Dr. Joseph O'Neill, Chief Executive Officer and President of The Immune Response Corporation. "Our clinical findings indicate that NeuroVax(TM) induces strong, disease-specific immune responses in essentially all the MS patients treated. We are eager to continue with additional Phase II studies and will launch a 300-patient trial later this year in Eastern Europe and the United States that will test the clinical benefit of NeuroVax(TM) by assessing its effect on MRI and relapse rates."

    New data indicates that an important part of the strong disease-specific immune response induced by NeuroVax(TM) is the stimulation of FOXP3+ Regulatory T-cells. This exciting approach could play an important role in the treatment of MS and other autoimmune diseases, such as rheumatoid arthritis, psoriasis and Crohn's disease.

    The Scientific Advisory Board guiding the development of NeuroVax(TM) will consist of six members:

    Dr. Jack Antel is a professor in the Department of Neurology and Neurosurgery at McGill University. He is Co-Director of the Neuroinflammation Training Program sponsored by the Canadian Institute of Health Research (CIHR). In 2005, Dr. Antel received the National MS Society/American Academy of Neurology John Dystel Prize for MS Research. He is also an associate member of McGill's Department of Microbiology and Immunology and Coordinator of the MS Program at the Montreal Neurologic Institute.

    Dr. Dennis Bourdette is the Director of the MS Center of Oregon and Chair for the Department of Neurology at Oregon Health and Science University (OHSU), where he has been a faculty member since 1983. He is also a staff neurologist at the Portland Veterans Affairs Medical Center. Dr. Bourdette has published numerous articles on MS and is listed in the Best Doctors in America.

    Professor Giancarlo Comi is the Director of the Department of Neurology and Clinical Neurophysiology at San Raffaele Hospital in Milan, Italy. He is a professor of Neurology at the University Vita-Salute San Raffaele and has chaired its graduate school in neurology since 2001. His fields of interest are the study of the natural history, research and validation of new therapies in MS. Professor Comi has authored or co-authored more than 400 articles in peer-reviewed journals and edited six books.

    Professor Krzysztof W. Selmaj is the Chairman of the Department of Neurology at the Medical University in Lodz, Poland, and serves as the Chairman of the European Federation of Neurology. He has received several honors and awards, including the Polish Academy of Science Sniadecki Award and the Polish Science Foundation Award. Professor Selmaj has authored numerous articles about neurology and MS and is on the editorial boards of the Journal of Neuroimmunology and European Journal of Neurology.

    Dr. Arthur Vandenbark is a senior research career scientist at the Portland Veterans Affairs Medical Center, and a professor in the Departments of Neurology and Molecular Microbiology and Immunology at OHSU. An inventor and pioneer of the TCR peptide vaccination approach for MS, Dr. Vandenbark is the recipient of the Javits Neuroscience Investigator Award. He has published numerous articles in the area of MS and its animal models.

    Dr. Jerry S. Wolinsky directs the Multiple Sclerosis Research Group and the Magnetic Resonance Imaging Analysis Center at the Graduate School of Biomedical Sciences at the University of Texas Health Science Center at Houston. He chairs the Research Programs Advisory Committee of the National MS Society and is the Chair of the Americas Committee for Treatment and Research in MS. Dr. Wolinsky is an associate editor of ACP Medicine and on the editorial board of Multiple Sclerosis: Clinical and Laboratory Research. He is recognized in The Best Doctors in America and America's Top Doctors.

    Forming a Scientific Advisory Board for NeuroVax(TM) is part of a new strategic initiative to leverage The Immune Response Corporation's core immune-based technology for autoimmune and infectious diseases. Specifically, this strategy will focus on the accelerated development of the Company's most promising immune-based therapies currently in clinical trials, NeuroVax(TM) for MS and IR103 for human immunodeficiency virus (HIV).

    About Multiple Sclerosis

    MS is an autoimmune disease in which the immune system mistakenly attacks normal tissues of the central nervous system. It afflicts approximately 400,000 people in the United States and more than 2.5 million worldwide (source: National MS Society). The disease is caused by activation of a specific subset of the patient's own white blood cells, pathogenic T-cells, which then attack a fatty tissue called myelin that surrounds and protects nerve fibers and creates scarring (sclerosis) that interferes with the normal transmission of nerve impulses. This damage, in turn, leads to a variety of chronic and highly individual and unpredictable neurological symptoms, ranging from movement and balance problems to vision impairment.

    Autoimmune diseases such as MS may result from the failure of normal immune regulatory mechanisms to prevent proliferation of pathogenic T-cells. Specifically, Immune Response Corporation's research indicates that MS patients have diminished levels of FOXP3 message and protein expression levels in peripheral T-cells. This observation is the first to link a defect in functional peripheral immunoregulation to an established genetic marker, FOXP3, which previously has been shown to be involved in maintaining immune tolerance and repressing the development of autoimmune diseases such as MS.

    About The Immune Response Corporation

    The Immune Response Corporation  is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.

    NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific, cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.

    IR103 is based on the Company's patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE®, the Company's first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive, HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.

    NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time.

    Source: Immune Response Corporation (29/03/06)

    Immune Response reports good Neurovax Data

    Biopharmaceutical company Immune Response Corp. said Tuesday that preliminary clinical trial results show that its investigational vaccine NeuroVax restores immune cell activity in multiple sclerosis, or MS, patients to levels seen in healthy patients.

    In an ongoing clinical trial, MS patients given monthly injections of NeuroVax over one year had an increase in FOXP3, a gene marker that tracks immune cells called T-cells. In MS patients, FOXP3 abnormalities are associated with unregulated T-cells that run rampant and attack the fatty tissue that protects nerve fibers, causing a condition that results in movement and balance problems and impaired vision. The company said that patients given NeuroVax had more normal and regulated T-cell activity, reducing the immune system's attack on the nervous system. About 400,000 people in the United States and more than 2.5 million worldwide suffer from the disease.

    Source: Associated Press (08/12/05)

    New MS Vaccine Shows Promise

    Battling any disease can be draining but some can rob you of your strength more than others. Now a simple shot is giving patients with multiple sclerosis their energy back. WAVE 3 Medical Reporter Lori Lyle has the details.

    Multiple sclerosis, or MS, short-circuits the wiring in the brain, causing loss of feeling, vision problems, fatigue and weakness for about 400,000 Americans. But a new vaccine is showing promise in fighting the disease.

    Sue Carlson works up to 12 hours a day helping others feel better. But four years ago, she could barely muster enough energy to work a half day. Multiple sclerosis weakened the entire right side of her body.

    "I had to move a body part predominantly with my left side and prop it on pillows or towels or blankets in order to do the work I needed to do," she says.

    But after six months on an experimental vaccine called NeuroVax, her strength came back. "And it just kept getting better and better and better."

    NeuroVax works by increasing the number of disease-fighting white blood cells in the immune system. It did that for all 40 patients who received it.

    Unlike standard treatments, which have to be given daily or weekly, the vaccine only has to be given once a month, and it doesn't cause flu-like side effects.

    "What patients want are treatments that are not only effective, but also aren't not impacting their quality of life because of side effects," says Neurologist Dennis Bourdette, M.D., of Oregon Health & Science University in Portland.

    Researchers say the results are encouraging, but larger studies are needed before it can be approved.

    Neurologist Arthur Vandenbark, Ph.D., also of Oregon Health & Science University and Portland V.A. Medical Center, says, "We still have to have a large enough trial that goes on for a minimum of two years where we see a difference between the vaccinated patients and the control group or the placebo group."

    After a year without an injection, Carlson is waiting for a new trial to begin, hoping that another dose of the vaccine will give her even more strength.

    Patients say the only side effect of the vaccine is a sore arm.

    Source: WAVE 3(08/12/05)

    © Multiple Sclerosis Resource Centre

    Related Items
    Ampyra (Fampyra)
    ATX-MS-1467
    Aubagio® (Teriflunomide)
    Avonex®
    AZ01
    Betaseron® (Betaferon®)
    BG-12
    Cannabis And Cannabinoid Research
    Copaxone®
    Cyclophosphamide
    Cyrevia
    Dextromethorphan
    Gilenya® (fingolimod)
    Laquinimod
    Lemtrada (alemtuzumab)
    Lisinopril
    Low Dose Naltrexone - Latest News
    Masitinib
    MIS416
    MN-166 (Ibudilast)
    Novantrone (Mitoxantrone)
    NT-KO-003
    Ocrelizumab
    ONO-4641
    PEGylated interferon beta
    PI-2301
    Rebif®
    RPC1063
    RPI-78M
    RTL-1000
    Sativex®
    SHK
    Statins
    Tcelna(TM)
    Trimesta (Oral Estriol)
    Tysabri®
    Zenapax (daclizumab)


    Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.